滚动资讯
FierceBiotechBlackstone closes record $6.3B life sciences fundFierceBiotechAstellas axes early Sjögren’s trial in latest setback for autoimmune disease communityFierceBiotechJohnson & Johnson’s Impella pumps miss the mark in 2 major coronary studiesBioPharma DiveUnited rises on IPF data; Biogen scores positive lupus data and an approvalEndpoints News#ACC26: Merck touts comparator data for oral cholesterol drugEndpoints News#AAD26 roundup: Takeda, Alumis, Priovant and Incyte take the stageEndpoints NewsDrugmakers skeptical of new White House overtures on pricingEndpoints NewsSamsung Bio union workers threaten strike over pay, disclosure of employee dataEndpoints NewsPost-Hoc Live: Will MAHA vaccine policies be a political problem for Republicans?FierceBiotechViridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincingFierceBiotechKevin Tang uses newfound control of Aurinia to finally take over KezarFierceBiotechBoston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
FierceBiotech 2026年3月30日

Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

Johnson & Johnson’s Impella pumps miss the mark in 2 major coronary studies

原文
暂时没有全文，请查看原始来源。

目录

59 全部